These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18493232)

  • 1. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
    Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
    Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
    Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
    Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
    Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
    Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
    Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
    Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
    Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
    Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
    Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
    Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
    Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
    Ferrandina G; Ludovisi M; Lorusso D; Pignata S; Breda E; Savarese A; Del Medico P; Scaltriti L; Katsaros D; Priolo D; Scambia G
    J Clin Oncol; 2008 Feb; 26(6):890-6. PubMed ID: 18281662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
    Ferrandina G; Paris I; Ludovisi M; D'Agostino G; Testa A; Lorusso D; Zanghi M; Pisconti S; Pezzella G; Adamo V; Breda E; Scambia G
    Gynecol Oncol; 2005 Aug; 98(2):267-73. PubMed ID: 15975643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
    Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
    Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
    Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
    Petru E; Angleitner-Boubenizek L; Reinthaller A; Deibl M; Zeimet AG; Volgger B; Stempfl A; Marth C
    Gynecol Oncol; 2006 Aug; 102(2):226-9. PubMed ID: 16443259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
    El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
    J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
    D'Agostino G; Ferrandina G; Ludovisi M; Testa A; Lorusso D; Gbaguidi N; Breda E; Mancuso S; Scambia G
    Br J Cancer; 2003 Oct; 89(7):1180-4. PubMed ID: 14520442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
    Martín M; Sánchez-Rovira P; Muñoz M; Baena-Cañada JM; Mel JR; Margeli M; Ramos M; Martínez E; García-Saenz JA; Casado A; Jaén AM; González-Farré X; Escudero MJ; Rodriguez-Martin C; Carrasco E;
    Ann Oncol; 2011 Dec; 22(12):2591-2596. PubMed ID: 21421542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
    Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.